TETRAPHASE PHAR (TTPH) Upgraded by Zacks to OUTPERFORM

Zacks Zacks Investment Research upgraded shares of TETRAPHASE PHAR (TTPH) from NEUTRAL to OUTPERFORM on November 17, 2014, with a target price of $25.80.

Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company's product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts.

Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.

To get a free copy of the research report on TETRAPHASE PHAR (TTPH),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .

Be the first to comment

Leave a Reply